Blogs

For more than a decade, pharma and biotech companies have lived with an uncomfortable truth: their supply chains are efficient, but fragile. COVID-19, geopolitical tensions, export controls, and logistics disruptions exposed a harsh reality that overdependence on a limited set...

In the pharmaceutical world, scaling up drug substance (API) manufacturing is a critical bridge between scientific innovation and patient access.

The journey from discovering a promising molecule to making it available in the market as a life-saving therapy is long, complex, and expensive.

Not too long ago, Contract Development and Manufacturing Organizations (CDMOs) were viewed simply as “the builders”, facilities where pharmaceutical companies outsourced production to save time or reduce costs. Their value was measured in efficiency, compliance, and scale.